Roth Capital Affirms Heat Biologics (HTBX) at 'Buy' Following HS-110 Combo Data
Tweet Send to a Friend
Roth Capital affirms Heat Biologics (Nasdaq: HTBX) with a Buy rating and $2 price target after announcing topline response and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE